Developer docs
API playgroundTry for free, no card

Search company profiles

immunitoAI

Full company profile

uuid0003fgv

Namestring
immunitoAI
Legal namestring
immunitoAI Private Limited
Websiteurl
immunitoai.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

immunitoAI is a Bengaluru-based TechBio company founded in 2020 that builds generative AI systems for de novo antibody design, serving pharmaceutical and biotechnology companies as its primary customer segment. Its proprietary platform uses deep neural networks trained on the structural complementarity between antibody paratopes and antigen epitopes to design antibody sequences computationally rather than via animal immunization, and to embed drug developability properties (stability, affinity, specificity) at the design stage. The company states a reduction in discovery timelines from the industry-standard 4-5 years to approximately 11-12 months.

The technology stack is paired with an in-house biological validation laboratory at C-CAMP in Bengaluru, where AI-designed sequences are synthesized and characterized, with experimental data feeding back into model training. Core products comprise an AI-powered antibody discovery platform and AI-generated novel antibody therapeutic candidates. The company has publicly emphasized three pillars: Design over Discovery (in silico generation without biological sources), Drug-First Antibodies (pre-defined developability properties), and a Structure-First AI Platform (shape-complementarity neural networks).

The business model is B2B enterprise: immunitoAI sells antibody discovery and screening services to pharma R&D and business development teams through direct field sales, multi-year contracts, and partnership agreements, with no public pricing disclosed. Following a $6.1M Series A in November 2025 led by Ashish Kacholia, the company has signaled a strategic shift toward building an internal proprietary antibody pipeline alongside its service offering. Total disclosed funding to date is approximately $7.54M across pre-seed, seed and Series A rounds, and the company maintains 11-50 employees across R&D, engineering and lab functions.

Short descriptiontext

immunitoAI is a Bengaluru-based TechBio company that uses generative AI to design novel antibody therapeutics de novo, serving pharmaceutical and biotechnology customers through enterprise discovery partnerships and an internal proprietary drug pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBangalore, India
HQ citystring
Bangalore
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody discovery platform, AI-driven therapeutics, de novo antibody design, biotech AI services, computational drug discovery
Industry4 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
AI-driven Antibody Discovery Services
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1AI-driven Antibody Discovery Services
TypeSubscription Recurring
Description

immunitoAI provides AI-powered antibody discovery and screening services to pharmaceutical and biotech companies. The company designs and identifies antibodies for specific protein targets using its proprietary AI platform, then validates candidates through in-house biological methods. Revenue is generated through service contracts and potentially through the development of proprietary antibody candidates.

economictimes.indiatimes.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Enterprise contracts for pharmaceutical companies
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing available; operates via direct enterprise sales, partnership agreements, and custom contracts with pharmaceutical companies for AI-driven antibody discovery services.

economictimes.indiatimes.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

immunitoAI develops and provides an AI-driven antibody discovery service that uses proprietary generative AI neural networks to design novel antibody therapeutics from scratch, without relying on animal or human biological sources. The platform embeds pre-defined drug properties (stability, affinity, specificity, developability) at the design inception and validates candidates through an in-house biological laboratory at C-CAMP, Bengaluru. The service targets pharmaceutical and biotech companies seeking faster, more efficient antibody discovery compared to conventional 4-5 year timelines.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Reduces antibody development timeline from 4-5 years to 11-12 months
+3 more records
Product overview1 text field

immunitoAI operates as a TechBio company with a single unified product offering: an AI-powered antibody discovery platform that generates novel antibody therapeutics from scratch. The platform is powered by proprietary generative AI neural networks trained on structural complementarity between antibodies and antigens. The core platform designs antibodies with pre-defined drug characteristics, which are then synthesized, characterized, and validated in the company's in-house biological laboratory. The platform rests on three foundational pillars: Design over Discovery (de novo antibody design without biological sources), Drug-First Antibodies (pre-defined drug properties embedded at inception), and Structure-First AI Platform (neural networks trained on shape complementarity). This integrated computational-biological approach aims to reduce antibody development time from 4-5 years to 11-12 months.

Product and service2 records
1AI-Powered Antibody Discovery Platform
CategoryAntibody Discovery Services
Description

immunitoAI's proprietary generative AI platform that designs novel antibodies and antibody fragments from scratch using deep neural networks trained on structural complementarity between antibody paratopes and antigen epitopes. The platform is offered to pharmaceutical and biotech companies as an antibody discovery service with in-house biological validation of generated candidates.

2AI-Generated Novel Antibody Therapeutics
CategoryTherapeutic Antibody Pipeline
Description

Therapeutic antibody candidates generated by immunitoAI's AI platform with pre-defined drug properties (stability, affinity, specificity, developability) embedded at the design inception. Antibodies are designed for specific protein targets including oncology and autoimmune disease indications and validated through in-house biological methods as part of the company's drug pipeline.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierSupportingTypeGTM or Marketing PartnerAnnounced on2024-12-01
Description

As a MeitY-supported startup, immunitoAI showcased its AI-powered antibody drug discovery platform at TiE Global Summit 2024 among 3,000+ attendees including investors, industry leaders, and enthusiasts.

Strategic tierSupportingTypeGTM or Marketing PartnerAnnounced on2024-10-01
Description

immunitoAI was selected for NASSCOM GenAI Foundry's second cohort, participating in an intensive two-day bootcamp covering AI development aspects and connecting with industry experts.

Strategic tierSupportingTypeGTM or Marketing PartnerAnnounced on2023-12-01
Description

immunitoAI was selected as one of 20 AI-first startups from 720+ applicants for Google for Startups Accelerator India Class 8. The four-month program provided mentorship, investor access, technical support, and concluded with Demo Day on April 5th, 2024.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-01
Description

immunitoAI's biological laboratory is incubated at C-CAMP in Bengaluru. The company participates in C-CAMP events and programs including Sugar Rush with Science talks and MeitY-supported programs through the C-CAMP DigitalTechSolutions cohort.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Placeholder not used.

TypeDirect peer
Description

AbCellera operates an AI-powered antibody discovery platform that partners with pharma to identify lead candidates from immune repertoires, directly competing with immunitoAI's AI antibody design services for pharma customers.

TypeDirect peer
Description

Absci combines generative AI with a wet-lab platform for de novo antibody design, the closest direct analog to immunitoAI's drug-first, structure-first approach to therapeutic antibody creation.

TypeDirect peer
Description

Generate Biomedicines uses generative AI to program novel protein therapeutics from scratch, directly competing with immunitoAI in de novo antibody and protein design for pharma partners.

TypeDirect peer
Description

BigHat Biosciences designs antibodies using ML integrated with a high-throughput wet lab, closely mirroring immunitoAI's structure-first AI platform combined with in-house biological validation.

TypeDirect peer
Description

Cradle applies generative AI and ML to protein engineering across modalities, overlapping with immunitoAI's AI-driven antibody and therapeutic protein design capabilities.

7Antiverse
TypeDirect peer
Description

Antiverse uses AI/ML for antibody design with a focus on difficult targets, comparable to immunitoAI's structure-first approach aimed at previously undruggable antigens.

8Isomorphic Labs
TypeBroad incumbent
Description

Alphabet's Isomorphic Labs applies DeepMind's protein-structure AI to drug discovery broadly, including antibody design, and is a well-capitalized incumbent in the same AI-first biologics space as immunitoAI.

TypeRegional player
Description

India-headquartered CRO/CDMO offering antibody discovery and development services, geographically adjacent and thematically comparable to immunitoAI as a Bengaluru-based biologics services platform.

10Syngene International
TypeRegional player
Description

India-based CRO with biologics discovery capabilities including antibody work, comparable to immunitoAI as a domestic Indian provider of antibody-related services to global pharma.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

immunitoAI

AI-driven Antibody Discovery Servicesimmunitoai.com

immunitoAI is a Bengaluru-based TechBio company that uses generative AI to design novel antibody therapeutics de novo, serving pharmaceutical and biotechnology customers through enterprise discovery partnerships and an internal proprietary drug pipeline.

What immunitoAI does

immunitoAI is a Bengaluru-based TechBio company founded in 2020 that builds generative AI systems for de novo antibody design, serving pharmaceutical and biotechnology companies as its primary customer segment. Its proprietary platform uses deep neural networks trained on the structural complementarity between antibody paratopes and antigen epitopes to design antibody sequences computationally rather than via animal immunization, and to embed drug developability properties (stability, affinity, specificity) at the design stage. The company states a reduction in discovery timelines from the industry-standard 4-5 years to approximately 11-12 months.

The technology stack is paired with an in-house biological validation laboratory at C-CAMP in Bengaluru, where AI-designed sequences are synthesized and characterized, with experimental data feeding back into model training. Core products comprise an AI-powered antibody discovery platform and AI-generated novel antibody therapeutic candidates. The company has publicly emphasized three pillars: Design over Discovery (in silico generation without biological sources), Drug-First Antibodies (pre-defined developability properties), and a Structure-First AI Platform (shape-complementarity neural networks).

The business model is B2B enterprise: immunitoAI sells antibody discovery and screening services to pharma R&D and business development teams through direct field sales, multi-year contracts, and partnership agreements, with no public pricing disclosed. Following a $6.1M Series A in November 2025 led by Ashish Kacholia, the company has signaled a strategic shift toward building an internal proprietary antibody pipeline alongside its service offering. Total disclosed funding to date is approximately $7.54M across pre-seed, seed and Series A rounds, and the company maintains 11-50 employees across R&D, engineering and lab functions.

immunitoAI firmographics

Firmographics
Name
immunitoAI
Legal name
immunitoAI Private Limited
Website
https://immunitoai.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
immunitoAI is a Bengaluru-based TechBio company that uses generative AI to design novel antibody therapeutics de novo, serving pharmaceutical and biotechnology customers through enterprise discovery partnerships and an internal proprietary drug pipeline.
Ownership category
akta.pro rank

immunitoAI industry classification

Industry
Product category
AI-driven Antibody Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Antibody discovery platform
  • AI-driven therapeutics
  • De novo antibody design
  • Biotech AI services
  • Computational drug discovery

Where immunitoAI is headquartered

Location

Headquarters

HQ city
Bangalore
HQ country
India
HQ region
Asia

Offices2 records

Markets served

immunitoAI business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. AI-driven Antibody Discovery Services: immunitoAI provides AI-powered antibody discovery and screening services to pharmaceutical and biotech companies. The company designs and identifies antibodies for specific protein targets using its proprietary AI platform, then validates candidates through in-house biological methods. Revenue is generated through service contracts and potentially through the development of proprietary antibody candidates.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise contracts for pharmaceutical companies

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

immunitoAI product offering

Product offering

Core offering

immunitoAI develops and provides an AI-driven antibody discovery service that uses proprietary generative AI neural networks to design novel antibody therapeutics from scratch, without relying on animal or human biological sources. The platform embeds pre-defined drug properties (stability, affinity, specificity, developability) at the design inception and validates candidates through an in-house biological laboratory at C-CAMP, Bengaluru. The service targets pharmaceutical and biotech companies seeking faster, more efficient antibody discovery compared to conventional 4-5 year timelines.

Product overview

immunitoAI operates as a TechBio company with a single unified product offering: an AI-powered antibody discovery platform that generates novel antibody therapeutics from scratch. The platform is powered by proprietary generative AI neural networks trained on structural complementarity between antibodies and antigens. The core platform designs antibodies with pre-defined drug characteristics, which are then synthesized, characterized, and validated in the company's in-house biological laboratory. The platform rests on three foundational pillars: Design over Discovery (de novo antibody design without biological sources), Drug-First Antibodies (pre-defined drug properties embedded at inception), and Structure-First AI Platform (neural networks trained on shape complementarity). This integrated computational-biological approach aims to reduce antibody development time from 4-5 years to 11-12 months.

Differentiator

Problem solved

Functional benefit

Products and services

  • AI-Powered Antibody Discovery Platform immunitoAI's proprietary generative AI platform that designs novel antibodies and antibody fragments from scratch using deep neural networks trained on structural complementarity between antibody paratopes and antigen epitopes. The platform is offered to pharmaceutical and biotech companies as an antibody discovery service with in-house biological validation of generated candidates.
  • AI-Generated Novel Antibody Therapeutics Therapeutic antibody candidates generated by immunitoAI's AI platform with pre-defined drug properties (stability, affinity, specificity, developability) embedded at the design inception. Antibodies are designed for specific protein targets including oncology and autoimmune disease indications and validated through in-house biological methods as part of the company's drug pipeline.

Quantifiable outcome

  • Reduces antibody development timeline from 4-5 years to 11-12 months
  • +3 more outcomes

Companies that use immunitoAI

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

immunitoAI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

immunitoAI partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered supporting and core.

  • TiE Global Summit 2024supportingGTM or Marketing Partner · 1 December 2024As a MeitY-supported startup, immunitoAI showcased its AI-powered antibody drug discovery platform at TiE Global Summit 2024 among 3,000+ attendees including investors, industry leaders, and enthusiasts.
  • NASSCOM GenAI FoundrysupportingGTM or Marketing Partner · 1 October 2024immunitoAI was selected for NASSCOM GenAI Foundry's second cohort, participating in an intensive two-day bootcamp covering AI development aspects and connecting with industry experts.
  • Google for Startups AcceleratorsupportingGTM or Marketing Partner · 1 December 2023immunitoAI was selected as one of 20 AI-first startups from 720+ applicants for Google for Startups Accelerator India Class 8. The four-month program provided mentorship, investor access, technical support, and concluded with Demo Day on April 5th, 2024.
  • Centre for Cellular and Molecular Platforms (C-CAMP)coreStrategic or Co-development Partner · 1 June 2023immunitoAI's biological laboratory is incubated at C-CAMP in Bengaluru. The company participates in C-CAMP events and programs including Sugar Rush with Science talks and MeitY-supported programs through the C-CAMP DigitalTechSolutions cohort.

Scale indicators5 records

Recent moves4 records

Expansion highlights5 records

immunitoAI competitors and assessment

Company assessment

Others

Direct peers

  • AbCellera Biologics: AbCellera operates an AI-powered antibody discovery platform that partners with pharma to identify lead candidates from immune repertoires, directly competing with immunitoAI's AI antibody design services for pharma customers.
  • Absci: Absci combines generative AI with a wet-lab platform for de novo antibody design, the closest direct analog to immunitoAI's drug-first, structure-first approach to therapeutic antibody creation.
  • Generate Biomedicines: Generate Biomedicines uses generative AI to program novel protein therapeutics from scratch, directly competing with immunitoAI in de novo antibody and protein design for pharma partners.
  • BigHat Biosciences: BigHat Biosciences designs antibodies using ML integrated with a high-throughput wet lab, closely mirroring immunitoAI's structure-first AI platform combined with in-house biological validation.
  • Cradle Bio: Cradle applies generative AI and ML to protein engineering across modalities, overlapping with immunitoAI's AI-driven antibody and therapeutic protein design capabilities.
  • Antiverse: Antiverse uses AI/ML for antibody design with a focus on difficult targets, comparable to immunitoAI's structure-first approach aimed at previously undruggable antigens.

Broad incumbents

  • Isomorphic Labs: Alphabet's Isomorphic Labs applies DeepMind's protein-structure AI to drug discovery broadly, including antibody design, and is a well-capitalized incumbent in the same AI-first biologics space as immunitoAI.

Regional players

  • Aragen Life Sciences: India-headquartered CRO/CDMO offering antibody discovery and development services, geographically adjacent and thematically comparable to immunitoAI as a Bengaluru-based biologics services platform.
  • Syngene International: India-based CRO with biologics discovery capabilities including antibody work, comparable to immunitoAI as a domestic Indian provider of antibody-related services to global pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

immunitoAI social profiles

Digital presence

immunitoAI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

immunitoAI leadership team

Management profile

Number of profiles

Profiles11 records

immunitoAI funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

immunitoAI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about immunitoAI

What does immunitoAI do?

immunitoAI develops and provides an AI-driven antibody discovery service that uses proprietary generative AI neural networks to design novel antibody therapeutics from scratch, without relying on animal or human biological sources. The platform embeds pre-defined drug properties (stability, affinity, specificity, developability) at the design inception and validates candidates through an in-house biological laboratory at C-CAMP, Bengaluru. The service targets pharmaceutical and biotech companies seeking faster, more efficient antibody discovery compared to conventional 4-5 year timelines.

Is immunitoAI a public or private company?

immunitoAI is a private company. It is classified as venture growth investor backed and is currently operating.

When was immunitoAI founded?

immunitoAI was founded in 2020. It employs 11 to 50 people.

Where is immunitoAI based?

immunitoAI is headquartered in Bangalore, India, in the Asia region.

How does immunitoAI make money?

One revenue line is on record: AI-driven Antibody Discovery Services.

Who are immunitoAI's main competitors?

AbCellera Biologics (Note: already listed) is listed as an others. Direct peers are AbCellera Biologics, Absci, Generate Biomedicines, BigHat Biosciences, Cradle Bio and Antiverse. Isomorphic Labs is listed as a broad incumbent. Regional players are Aragen Life Sciences and Syngene International.

Does immunitoAI have an API?

No public API is recorded for immunitoAI.

What industry is immunitoAI in?

immunitoAI's product category is AI-driven Antibody Discovery Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YourStoryCan AI find the right antibody for a drug target? ImmunitoAI thinks soImmunitoAI, a Bengaluru-based startup, uses AI to design antibodies for drug targets, testing them in its lab. The company raised Rs 52.14 crore in a Series A round, with total funding of Rs 66.98 crore. It plans to expand into the US and Europe and upgrade its platform.The KenPlucky founders, not Indian pharma giants, could reshape drug discovery in its new ‘golden age’A feature article examines how AI is transforming drug discovery, with 173 AI-discovered drugs entering clinical trials since 2021, while arguing that small Indian biotech founders rather than large pharma companies may be better positioned to capitalize on this shift. The article highlights ImmunitoAI as an example of an Indian startup using AI to design drug candidates faster, in contrast to major Indian pharma firms like Glenmark and Wockhardt that have invested heavily in traditional drug discovery. Despite promising technological advances globally, Indian drug discovery biotechs face significant funding challenges, as domestic venture capital remains reluctant to support the high-risk, capital-intensive field.Entrepreneur IndiaAridni Shah, Co-founder and CEO, immunitoAIAridni Shah is the co-founder and CEO of immunitoAI Pvt. Ltd., a biotech company involved in therapeutics research. She has an extensive research background and international collaboration experience, with her work focused on molecular mechanisms in learning and memory.Digital Health NewsimmunitoAI Raises $6.1M To Expand AI-Led Antibody Therapeutics PipelineBengaluru-based biotech startup immunitoAI has raised $6.1 million in a Series A funding round led by Ashish Kacholia to scale its AI-driven antibody development platform. The capital will support the creation of proprietary, IP-backed antibody therapeutics designed using generative AI models, which aim to compress development timelines from years to months. This investment highlights growing investor interest in AI-first biotech innovation within India's healthcare ecosystem.Inc42immunitoAI Bags $6.1 Mn From pi Ventures, Others To Develop Antibody TreatmentBengaluru-based AI startup immunitoAI has raised $6.1 million in Series A funding led by investor Ashish Kacholia, who infused around $3 million, with participation from pi Ventures ($1.25 million), Anicut Capital ($1 million), and other investors including 3one4 Capital and AC Ventures. Founded in 2020, the company operates an AI platform that designs antibody therapeutics from scratch without traditional biological sources, reducing development time from 4-5 years to 11-12 months. The startup, currently pre-revenue, plans to develop antibodies as its IP and target pharma companies as clients, with the global monoclonal antibodies market projected to grow from $226.63 billion in 2023 to over $729 billion by 2033.InvsttExploring Life Sciences- Navigating Biotech and Healthcare InnovationsThe article presents a curated list of startups in the Life Sciences sector, including Powercity Energy, Jayma Bio Innovations, Midas Lifecare, and Immunito AI, detailing their respective innovations in energy, healthcare, and biotechnology. Each entry outlines the company's specific focus area, such as AI-driven drug discovery or renewable energy solutions, along with key operational details like funding status or valuation where available. The compilation serves as an overview of emerging entities driving innovation within the Indian life sciences ecosystem.SiliconindiaBiotech startup immunitoAI raises USD1 Million in seed round led by pi VenturesBiotech startup immunitoAI raised $1 million in a seed funding round led by pi Ventures, with participation from Entrepreneur First. The company plans to utilize the capital for product development and industry partnerships to advance its AI-led platform for antibody discovery.GreyBAI in Antibody Development: 3 Startups showing PromiseAn article outlines how AI and machine learning are being applied to antibody discovery, design, engineering and screening, citing time and cost reductions across development stages. It highlights three startups: Denovai Biotech, which aims to compress discovery and screening to under a year, ImmunitoAI, which reduced engineering and optimization to hours and raised $1 million in 2021 with Google investment, and EVQLV, which scaled from 10,000 to 1 million antibody analyses in 24 hours.TechcircleClever Harvey, immunitoAI, OckyPocky, Setu, others raise early-stage capitalClever Harvey, immunitoAI, OckyPocky, Setu, GameEon, Farmers Fresh Zone, BeatO, and Stride Ahead raised early-stage capital. Clever Harvey secured $1.5M pre-Series A, immunitoAI raised $1M seed, and Farmers Fresh Zone raised Rs 6 crore pre-Series A. The funds will support product expansion, hiring, and platform development.